Trial Profile
Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Miglustat (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 04 Apr 2014 New trial record
- 11 Apr 2009
- 24 Sep 2008